Global In Vivo Toxicology Market Size study, by Product (Instruments, Consumables), by Test Type (Acute, Sub-acute, Sub-chronic, Chronic test type), by Testing Facility (Outsourced testing facility, In-house testing facility), by Toxicity End Point (Immun

Global In Vivo Toxicology Market Size study, by Product (Instruments, Consumables), by Test Type (Acute, Sub-acute, Sub-chronic, Chronic test type), by Testing Facility (Outsourced testing facility, In-house testing facility), by Toxicity End Point (Immunotoxicity, Systemic toxicity, Carcinogenicity, Genotoxicity, Developmental & reproductive toxicity (DART), Other toxicity endpoints), by End User (Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Other End Users), and Regional Forecasts 2022-2032

Global In Vivo Toxicology Market was valued at USD 5.49 billion in 2023 and is projected to grow with a healthy growth rate of more than 5.6% over the forecast period 2024-2032. In vivo toxicology, a critical branch of toxicology, involves studying the toxic effects of substances on live animal models. This field is pivotal for understanding the absorption, distribution, metabolism, and excretion (ADME) of various substances, providing indispensable insights into their potential toxicological impacts. Such studies are instrumental in ensuring the safety and efficacy of new pharmaceuticals, chemicals, and other products before they reach the market.
The market for in vivo toxicology is driven by several compelling factors. Firstly, the relentless advancement in drug development within the pharmaceutical industry necessitates comprehensive in vivo toxicology studies. These studies are indispensable for ascertaining the safety and efficacy of new compounds before they proceed to clinical trials. The burgeoning prevalence of chronic diseases and the incessant need for novel treatments propel the pharmaceutical sector's investment in research and development, thereby augmenting the demand for in vivo toxicology testing. Additionally, stringent regulatory frameworks that mandate exhaustive safety assessments of drugs and chemicals further drive the market. Regulatory bodies, including the FDA and EMA, require extensive toxicological evaluations to ensure new products' safety, compelling companies to conduct in vivo toxicology studies to meet compliance standards. Technological advancements have significantly enhanced the precision and efficiency of in vivo toxicology studies. Innovations in imaging technologies, biomarkers, and data analysis tools allow researchers to obtain more accurate and detailed insights into substances' effects on living organisms. These advancements reduce the time and cost associated with toxicology testing, encouraging broader adoption and market growth. Furthermore, the expanding biotechnology sector and the rising focus on personalized medicine create substantial growth opportunities for the market. However, ethical and animal welfare concerns associated with animal testing pose significant challenges. Increasing scrutiny from animal rights organizations and the public has led to calls for alternative testing methods, potentially impacting the demand for traditional in vivo toxicology studies.
North America, particularly the US and Canada, dominated the market in 2023, accounting for the highest market share. This dominance is attributed to the region's high demand for personalized medicines and the expansion of the stem cell research sector in Canada, driven by large-scale investments and the implementation of the Canadian Stem Cell Strategy and Action Plan. The presence of well-established players and favourable government reimbursement policies further bolster the market in North America. The Asia Pacific region is expected to exhibit the fastest growth rate over the forecast period, driven by growing investments in healthcare infrastructure and increasing adoption of advanced testing methodologies.
Major market players included in this report are:
Charles River Laboratories (US)
The Jackson Laboratory (US)
Envigo (US)
Taconic Biosciences, Inc. (US)
JANVIER LABS (France)
Thermo Fisher Scientific (US)
Danaher Corporation (US)
Waters Corporation (US)
Agilent Technologies (US)
Shimadzu Corporation (Japan)
Bruker Corporation (US)
PerkinElmer (US)
Merck KGaA (Germany)
GE Healthcare (US)
Bio-Rad Laboratories (US)
The detailed segments and sub-segment of the market are explained below:
By Product:
• Instruments
• Consumables
By Test Type:
• Acute
• Sub-acute
• Sub-chronic
• Chronic test type
By Testing Facility:
• Outsourced testing facility
• In-house testing facility
By Toxicity End Point:
• Immunotoxicity
• Systemic toxicity
• Carcinogenicity
• Genotoxicity
• Developmental & reproductive toxicity (DART)
• Other toxicity endpoints
By End User:
• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Other End Users
By Region:
North America:
• U.S.
• Canada
Europe:
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific:
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America:
• Brazil
• Mexico
• RoLA
Middle East & Africa:
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.